215 related articles for article (PubMed ID: 22111602)
1. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Brown KC; Hosseinipour MC; Hoskins JM; Thirumaran RK; Tien HC; Weigel R; Tauzie J; Shumba I; Lamba JK; Schuetz EG; McLeod HL; Kashuba AD; Corbett AH
Pharmacogenomics; 2012 Jan; 13(1):113-21. PubMed ID: 22111602
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
[TBL] [Abstract][Full Text] [Related]
5. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Ciccacci C; Borgiani P; Ceffa S; Sirianni E; Marazzi MC; Altan AM; Paturzo G; Bramanti P; Novelli G; Palombi L
Pharmacogenomics; 2010 Jan; 11(1):23-31. PubMed ID: 20017669
[TBL] [Abstract][Full Text] [Related]
6. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.
Svärd J; Spiers JP; Mulcahy F; Hennessy M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):536-49. PubMed ID: 20861742
[TBL] [Abstract][Full Text] [Related]
7. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
[TBL] [Abstract][Full Text] [Related]
10. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
Chantarangsu S; Cressey TR; Mahasirimongkol S; Capparelli E; Tawon Y; Ngo-Giang-Huong N; Jourdain G; Lallemant M; Chantratita W
J Antimicrob Chemother; 2009 Dec; 64(6):1265-73. PubMed ID: 19812066
[TBL] [Abstract][Full Text] [Related]
12. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
Micheli JE; Chinn LW; Shugarts SB; Patel A; Martin JN; Bangsberg DR; Kroetz DL
Pharmacogenet Genomics; 2013 Nov; 23(11):591-6. PubMed ID: 23982262
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
Vardhanabhuti S; Acosta EP; Ribaudo HJ; Severe P; Lalloo U; Kumarasamy N; Taulo F; Kabanda J; Oneko O; Ive P; Sambarey P; Chan ES; Hitti J; Hong F; McMahon D; Haas DW;
J Infect Dis; 2013 Aug; 208(4):662-71. PubMed ID: 23687222
[TBL] [Abstract][Full Text] [Related]
14. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
Masebe TM; Bessong PO; Nwobegahay J; Ndip RN; Meyer D
Dis Markers; 2012; 32(1):43-50. PubMed ID: 22297601
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
[TBL] [Abstract][Full Text] [Related]
18. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ;
J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
[TBL] [Abstract][Full Text] [Related]
20. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Ribaudo HJ; Liu H; Schwab M; Schaeffeler E; Eichelbaum M; Motsinger-Reif AA; Ritchie MD; Zanger UM; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford D; Haas DW
J Infect Dis; 2010 Sep; 202(5):717-22. PubMed ID: 20662624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
